Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion

Archive ouverte

Métais, Alice | Tauziède-Espariat, Arnault | Garcia, Jeremy | Appay, Romain | Uro-Coste, Emmanuelle | Meyronet, David | Maurage, Claude Alain | Vandenbos, Fanny Burel | Rigau, Valérie | Chiforeanu, Dan Christian | Pallud, Johan | Senova, Suhan | Saffroy, Raphaël | Colin, Carole | Edjlali, Myriam | Varlet, Pascale | Figarella-Branger, Dominique F.

Edité par CCSD ; BioMed Central part of Springer Science -

International audience. Background: Gliomas with FGFR3::TACC3 fusion mainly occur in adults, display pathological features of glioblastomas (GB) and are usually classified as glioblastoma, IDH-wildtype. However, cases demonstrating pathological features of low-grade glioma (LGG) lead to difficulties in classification and clinical management. We report a series of 8 GB and 14 LGG with FGFR3:TACC3 fusion in order to better characterize them. Methods: Centralized pathological examination, search for TERT promoter mutation and DNA-methylation profiling were performed in all cases. Search for prognostic factors was done by the Kaplan–Meir method. Results: TERT promoter mutation was recorded in all GB and 6/14 LGG. Among the 7 cases with a methylation score > 0.9 in the classifier (v12.5), 2 were classified as glioblastoma, 4 as ganglioglioma (GG) and 1 as dysembryoplastic neuroepithelial tumor (DNET). t-SNE analysis showed that the 22 cases clustered into three groups: one included 12 cases close to glioblastoma, IDH-wildtype methylation class (MC), 5 cases each clustered with GG or DNET MC but none with PLNTY MC. Unsupervised clustering analysis revealed four groups, two of them being clearly distinct: 5 cases shared age (< 40), pathological features of LGG, lack of TERT promoter mutation, FGFR3(Exon 17)::TACC3(Exon 10) fusion type and LGG MC. In contrast, 4 cases shared age (> 40), pathological features of glioblastoma, and were TERT-mutated. Relevant factors associated with a better prognosis were age < 40 and lack of TERT promoter mutation. Conclusion: Among gliomas with FGFR3::TACC3 fusion, age, TERT promoter mutation, pathological features, DNA-methylation profiling and fusion subtype are of interest to determine patients’ risk.

Suggestions

Du même auteur

Phenotypic and epigenetic heterogeneity in FGFR2 ‐fused glial and glioneuronal tumours

Archive ouverte | Métais, Alice | CCSD

International audience. Aims FGFR ‐fused central nervous system (CNS) tumours are rare and are usually within the glioneuronal and neuronal tumours or the paediatric‐type diffuse low‐grade glioma spectrum. Among thi...

CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas

Archive ouverte | Tauziède-Espariat, Arnault | CCSD

International audience. A novel methylation class, “neuroepithelial tumor, with PLAGL1 fusion” (NET-PLAGL1), has recently been described, based on epigenetic features, as a supratentorial pediatric brain tumor with ...

CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population

Archive ouverte | Tauziède-Espariat, Arnault | CCSD

International audience. The Central Nervous System (CNS) tumor with BCOR internal tandem duplication (ITD) has recently been added as a novel embryonal histomolecular tumor type to the 2021 World Health Organization...

Chargement des enrichissements...